$1.57
7.53% yesterday
NYSE, Apr 07, 10:09 pm CET
ISIN
US20454B1044
Symbol
CMPX
Sector
Industry

Compass Therapeutics Target price 2025 - Analyst rating & recommendation

Compass Therapeutics Classifications & Recommendation:

Buy
100%

Compass Therapeutics Price Target

Target Price $13.10
Price $1.57
Potential
Number of Estimates 10
10 Analysts have issued a price target Compass Therapeutics 2026 . The average Compass Therapeutics target price is $13.10. This is higher than the current stock price. The highest price target is
$32.00 1,938.22%
register free of charge
, the lowest is .
A rating was issued by 10 analysts: 10 Analysts recommend Compass Therapeutics to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Compass Therapeutics stock has an average upside potential 2026 of . Most analysts recommend the Compass Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.36 -0.48
9.09% 33.33%
P/E negative

10 Analysts have issued a Compass Therapeutics forecast for earnings per share. The average Compass Therapeutics EPS is

$-0.48
Unlock
. This is
33.33% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.19 47.22%
Unlock
, the lowest is
$-0.66 83.33%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.36 9.09%
2025
$-0.48 33.33%
Unlock
2026
$-0.55 14.58%
Unlock
2027
$-0.21 61.82%
Unlock
2028
$0.44 309.52%
Unlock
2029
$0.84 90.91%
Unlock

P/E ratio

Current -4.37 14.15%
2025
-3.28 24.94%
Unlock
2026
-2.86 12.80%
Unlock
2027
-7.52 162.94%
Unlock
2028
3.56 147.34%
Unlock
2029
1.87 47.47%
Unlock

Current Compass Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Apr 04 2025
Leerink Partners
Locked
Locked
Locked Apr 02 2025
Guggenheim
Locked
Locked
Locked Apr 02 2025
D. Boral Capital
Locked
Locked
Locked Apr 01 2025
D. Boral Capital
Locked
Locked
Locked Feb 27 2025
D. Boral Capital
Locked
Locked
Locked Feb 25 2025
Guggenheim
Locked
Locked
Locked Feb 24 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 04 2025
Locked
Leerink Partners:
Locked
Locked
Apr 02 2025
Locked
Guggenheim:
Locked
Locked
Apr 02 2025
Locked
D. Boral Capital:
Locked
Locked
Apr 01 2025
Locked
D. Boral Capital:
Locked
Locked
Feb 27 2025
Locked
D. Boral Capital:
Locked
Locked
Feb 25 2025
Locked
Guggenheim:
Locked
Locked
Feb 24 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today